Form 4: VolitionRx Secretary Awarded 119,000 RSUs

VolitionRx's Secretary, Rodney Gerard Rootsaert, received an award of 119,000 restricted stock units in lieu of cash compensation, vesting over time.

Summary

• Rodney Gerard Rootsaert, Secretary of VOLITIONRX LTD (VNRX), was awarded 119,000 restricted stock units (RSUs) on February 26, 2026.
• The RSUs were granted under the Issuer's 2024 Stock Incentive Plan and are in lieu of cash compensation that would otherwise have been owed.
• The RSUs will be earned in twelve approximately equal monthly installments, commencing on March 1, 2026.
• Once earned, the RSUs are subject to additional time-based vesting in a single installment on February 26, 2027.
• Vesting is generally contingent on the reporting person's continued service throughout each applicable earning and vesting date.
• Upon vesting and settlement, the reporting person will receive common stock equal to the number of earned and vested RSUs.
• Following this transaction, Rodney Gerard Rootsaert directly beneficially owns 281,262 shares of common stock.
• Additionally, 1,007,718 shares of common stock are indirectly beneficially owned through Concord International, Inc., where Mr. Rootsaert is a controlling director with shared voting and dispositive control.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices aimed at retaining key talent and aligning management incentives with long-term shareholder value, without indicating any significant operational changes.

Positives

• The RSU award aligns the interests of the Secretary, Rodney Gerard Rootsaert, with those of shareholders by tying a portion of his compensation to the company's future stock performance.
• Granting RSUs in lieu of cash compensation helps conserve the company's cash reserves, which can be beneficial for operational liquidity or other strategic investments.
• The multi-year vesting schedule (earning over 12 months, then vesting on February 26, 2027) acts as a retention mechanism, incentivizing continued service from a key executive.

Negatives

• The future issuance of 119,000 shares upon vesting and settlement of the RSUs will result in a minor dilution of existing shareholders' ownership, though this is a common practice for equity compensation.

Risks

• The RSUs are subject to continued service by the reporting person throughout each applicable earning and vesting date, meaning the award could be forfeited if employment ceases before full vesting.

Future Outlook

The awarded restricted stock units will be earned monthly starting March 1, 2026, and will vest in a single installment on February 26, 2027, contingent on continued service. This structure aims to retain the executive and align future compensation with company performance.

Industry Context

StockSavvy.ai notes that the award of restricted stock units (RSUs) to key executives in lieu of cash compensation is a common practice across various industries, particularly in growth-oriented companies. This method helps conserve cash while providing long-term incentives tied to shareholder value creation.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of executive compensation is a widely accepted and standard practice across public companies globally, including those in the biotechnology and diagnostics sectors where VolitionRx operates.
• Many companies, such as Exact Sciences Corp. (EXAS) or Guardant Health, Inc. (GH), utilize similar equity-based incentives to attract, retain, and motivate key personnel, aligning their interests with long-term shareholder value.
• The vesting schedule, which includes both an earning period and a subsequent time-based vesting event, is typical for RSU grants, designed to ensure executive retention and commitment over several years.

Related Party Transactions

• Rodney Gerard Rootsaert indirectly beneficially owns 1,007,718 shares of common stock through Concord International, Inc., where he is a controlling director and shares voting and dispositive control.

Stakeholder Impact

• Shareholders: The RSU award aligns the executive's long-term interests with shareholder value creation, potentially leading to more focused management decisions. However, it also introduces minor future dilution upon vesting.
• Employees: This transaction specifically impacts a key executive, reinforcing the company's compensation strategy for leadership.

Next Steps

• The reporting person will begin earning RSUs in twelve approximately equal monthly installments starting March 1, 2026.
• The earned RSUs will be subject to a final time-based vesting on February 26, 2027, contingent on continued service.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the award of restricted stock units. While it aligns management incentives with shareholder interests and conserves cash, it does not present new fundamental information or a significant change in the company's outlook that would warrant a change in investment recommendation. It is a standard practice for executive retention and motivation.

Keywords

VolitionRx, VNRX, Restricted Stock Units, RSU award, executive compensation, insider transaction, Form 4, equity compensation, corporate governance